XML 49 R9.htm IDEA: XBRL DOCUMENT v3.24.0.1
Consolidated Statements of Cash Flows - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Dec. 31, 2020
Operating activities:        
Net income $ 476,457 $ 339,540 $ 160,144 $ 74,000
Adjustments to reconcile net income to net cash provided by operating activities:        
Depreciation and amortization 338,654 343,507 318,202  
Provision for credit losses 49,650 34,835 38,191  
Gain on sale of discontinued operations (176,078) (35,456) 0  
Gain on sale of rental equipment and other property, plant and equipment (32,724) (31,196) (26,175)  
Amortization of debt discounts and debt issuance costs 11,211 12,064 14,033  
Fair value loss on common stock warrant liabilities 0 0 26,597  
Loss on extinguishment of debt 0 0 5,999  
Stock-based compensation expense 34,486 29,613 26,184  
Deferred income tax expense 141,641 100,849 36,563  
Loss on settlement of foreign currency forward contract 7,715 0 0  
Unrealized currency (gains) losses, net (1,374) 753 295  
Other 3,413 4,081 0  
Changes in operating assets and liabilities, net of effect of businesses acquired:        
Trade receivables (76,357) (94,463) (105,053)  
Inventories (3,276) (12,345) (9,083)  
Prepaid expenses and other assets (18,310) 149 3,324  
Operating lease assets and liabilities 1,045 856 473  
Accounts payable and other accrued expenses (14,836) 9,443 27,525  
Deferred revenue and customer deposits 19,923 42,428 22,683  
Net cash provided by operating activities 761,240 744,658 539,902  
Investing activities:        
Proceeds from sale of discontinued operations 403,992 325,611 0  
Acquisitions, net of cash acquired (561,629) (220,620) (147,172)  
Proceeds from sale of rental equipment 51,290 70,703 55,210  
Purchase of rental equipment and refurbishments (226,976) (443,138) (278,498)  
Payment for settlement of foreign currency forward contract (7,715) 0 0  
Proceeds from the sale of property, plant and equipment 13,272 1,775 16,911  
Purchase of property, plant and equipment (22,237) (43,664) (30,498)  
Net cash used in investing activities (350,003) (309,333) (384,047)  
Financing activities:        
Repurchase and cancellation of Common Stock and warrants (818,182) (751,795) (363,586)  
Receipts from issuance of Common Stock from the exercise of options 498 11,230 7,484  
Taxes paid on employee stock awards (14,171) (13,888) (7,177)  
Receipts from borrowings 1,911,230 964,308 728,677  
Repayment of borrowings (1,475,219) (588,808) (512,181)  
Payment of financing costs (6,457) (8,187) 0  
Principal payments on finance lease obligations (16,634) (42,228) (17,399)  
Payment of debt extinguishment premium costs 0 0 (3,705)  
Net cash used in financing activities (418,935) (429,368) (167,887)  
Effect of exchange rate changes on cash and cash equivalents 882 (882) (206)  
Net change in cash and cash equivalents (6,816) 5,075 (12,238)  
Cash and cash equivalents at the beginning of the period 17,774 12,699 24,937  
Cash and cash equivalents at the end of the period 10,958 17,774 12,699 $ 24,937
Supplemental cash flow information:        
Interest paid, net 184,863 130,463 103,795  
Income taxes paid, net 32,949 25,092 9,855  
Capital expenditures accrued or payable 19,557 21,052 27,667  
Reconciliation of cash and cash equivalents to the consolidated balance sheet:        
Cash and cash equivalents 10,958 7,390    
Continuing And Discontinued Operations        
Reconciliation of cash and cash equivalents to the consolidated balance sheet:        
Cash and cash equivalents 10,958 17,774 12,699  
Continuing Operations        
Adjustments to reconcile net income to net cash provided by operating activities:        
Fair value loss on common stock warrant liabilities 0 0 26,597  
Loss on extinguishment of debt 0 0 5,999  
Reconciliation of cash and cash equivalents to the consolidated balance sheet:        
Cash and cash equivalents 10,958 7,390 6,393  
Discontinued Operations        
Reconciliation of cash and cash equivalents to the consolidated balance sheet:        
Cash and cash equivalents $ 0 $ 10,384 $ 6,306